$TOVX
Theriva Biologics, Inc.

2014 Q2 Form 10-Q Financial Statement

#000114420414031292 Filed on May 15, 2014

View on sec.gov

Income Statement

Concept 2014 Q2 2014 Q1 2013 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.810M $1.120M $1.120M
YoY Change 43.65% 0.0% 15.46%
% of Gross Profit
Research & Development $2.837M $2.717M $1.118M
YoY Change 135.83% 143.02% 25.62%
% of Gross Profit
Depreciation & Amortization $10.00K $3.000K $11.00K
YoY Change 0.0% -72.73% -45.0%
% of Gross Profit
Operating Expenses $4.651M $3.839M $2.240M
YoY Change 88.99% 71.38% 21.08%
Operating Profit -$4.651M -$3.839M
YoY Change
Interest Expense $0.00 $0.00 $10.00K
YoY Change -100.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $95.00K $1.000K $12.00K
YoY Change -363.89% -91.67% 20.0%
Pretax Income -$4.651M -$3.839M -$2.240M
YoY Change 88.99% 71.38% 21.08%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.556M -$3.838M -$2.228M
YoY Change 82.46% 72.26% 85.67%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$2.731M -$2.299M -$1.756M
COMMON SHARES
Basic Shares Outstanding 58.45M shares 58.28M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q2 2014 Q1 2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.840M $11.16M $8.520M
YoY Change 13.95% 30.99% 25.29%
Cash & Equivalents $7.843M $11.16M $8.520M
Short-Term Investments
Other Short-Term Assets $1.389M $1.332M $2.190M
YoY Change -26.12% -39.18% 2637.5%
Inventory
Prepaid Expenses $52.00K $48.00K
Receivables
Other Receivables
Total Short-Term Assets $9.232M $12.49M $11.45M
YoY Change -2.38% 9.06% 56.21%
LONG-TERM ASSETS
Property, Plant & Equipment $51.00K $38.00K $220.0K
YoY Change -67.1% -82.73% -26.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K $10.00K $20.00K
YoY Change -50.0% -50.0% 0.0%
Total Long-Term Assets $57.00K $44.00K $230.0K
YoY Change -66.47% -80.87% -77.45%
TOTAL ASSETS
Total Short-Term Assets $9.232M $12.49M $11.45M
Total Long-Term Assets $57.00K $44.00K $230.0K
Total Assets $9.289M $12.53M $11.68M
YoY Change -3.51% 7.29% 39.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.079M $773.0K $200.0K
YoY Change 406.57% 286.5% -37.5%
Accrued Expenses $153.0K $0.00
YoY Change 856.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.232M $773.0K $200.0K
YoY Change 437.99% 286.5% -54.55%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.232M $773.0K $200.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.230M $773.0K $200.0K
YoY Change 437.12% 286.5% -54.55%
SHAREHOLDERS EQUITY
Retained Earnings -$89.65M -$85.10M
YoY Change 21.7%
Common Stock $97.71M $96.85M
YoY Change 17.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.057M $11.76M $11.49M
YoY Change
Total Liabilities & Shareholders Equity $9.289M $12.53M $11.68M
YoY Change -3.54% 7.29% 39.88%

Cashflow Statement

Concept 2014 Q2 2014 Q1 2013 Q1
OPERATING ACTIVITIES
Net Income -$4.556M -$3.838M -$2.228M
YoY Change 82.46% 72.26% 85.67%
Depreciation, Depletion And Amortization $10.00K $3.000K $11.00K
YoY Change 0.0% -72.73% -45.0%
Cash From Operating Activities -$3.300M -$3.470M -$1.660M
YoY Change 101.22% 109.04% 16.9%
INVESTING ACTIVITIES
Capital Expenditures -$20.00K $4.000K $3.000K
YoY Change 100.0% 33.33%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$20.00K -$4.000K $0.00
YoY Change 100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 $4.000K 230.0K
YoY Change -98.26% -85.06%
NET CHANGE
Cash From Operating Activities -3.300M -$3.470M -1.660M
Cash From Investing Activities -20.00K -$4.000K 0.000
Cash From Financing Activities 0.000 $4.000K 230.0K
Net Change In Cash -3.320M -$3.470M -1.430M
YoY Change 101.21% 142.66% -1291.67%
FREE CASH FLOW
Cash From Operating Activities -$3.300M -$3.470M -$1.660M
Capital Expenditures -$20.00K $4.000K $3.000K
Free Cash Flow -$3.280M -$3.474M -$1.663M
YoY Change 101.23% 108.9% 17.11%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11155000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14625000 USD
CY2014Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1332000 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1591000 USD
CY2014Q1 us-gaap Assets Current
AssetsCurrent
12487000 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
16216000 USD
CY2014Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
38000 USD
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12531000 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37000 USD
CY2014Q1 syn Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
6000 USD
CY2013Q4 syn Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
4000 USD
CY2014Q1 us-gaap Assets
Assets
12531000 USD
CY2013Q4 us-gaap Assets
Assets
16257000 USD
CY2014Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
773000 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
142000 USD
CY2014Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
0 USD
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
885000 USD
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
773000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1027000 USD
CY2014Q1 us-gaap Liabilities
Liabilities
773000 USD
CY2013Q4 us-gaap Liabilities
Liabilities
1027000 USD
CY2014Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
58000 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
58000 USD
CY2014Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
96796000 USD
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
96430000 USD
CY2014Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-85096000 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-81258000 USD
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
11758000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
15230000 USD
CY2014Q1 us-gaap Minority Interest
MinorityInterest
0 USD
CY2013Q4 us-gaap Minority Interest
MinorityInterest
0 USD
CY2014Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
11758000 USD
CY2013Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
15230000 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16257000 USD
CY2014Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
22000 USD
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2014Q1 syn Share Based Compensation Arrangement By Share Based Payment Award Options Expected Forfeiture Rate In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod
0 pure
CY2014Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58524052 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58295808 shares
CY2014Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58442570 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58214326 shares
CY2014Q1 syn Prepaid Expenses Research And Development
PrepaidExpensesResearchAndDevelopment
1163000 USD
CY2013Q4 syn Prepaid Expenses Research And Development
PrepaidExpensesResearchAndDevelopment
1361000 USD
CY2014Q1 us-gaap Prepaid Insurance
PrepaidInsurance
121000 USD
CY2013Q4 us-gaap Prepaid Insurance
PrepaidInsurance
177000 USD
CY2014Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
48000 USD
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
53000 USD
CY2014Q1 us-gaap Other Assets Current
OtherAssetsCurrent
1332000 USD
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1591000 USD
CY2014Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
60000 USD
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
56000 USD
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
19000 USD
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.48 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.26 pure
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0077 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0157 pure
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2013Q1 syn Share Based Compensation Arrangement By Share Based Payment Award Options Expected Forfeiture Rate In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod
0 pure
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1632501 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0 shares
CY2013 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
0 shares
CY2014Q1 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
221661 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
447672 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1632501 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
963168 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.99
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2013 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
0
CY2014Q1 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
1.48
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
1.89
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.99
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
2.15
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1122000 USD
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1122000 USD
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1118000 USD
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2717000 USD
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
2240000 USD
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
3839000 USD
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2240000 USD
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3839000 USD
CY2013Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
11000 USD
CY2014Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000 USD
CY2013Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000 USD
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2013Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12000 USD
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1000 USD
CY2013Q1 us-gaap Profit Loss
ProfitLoss
-2228000 USD
CY2014Q1 us-gaap Profit Loss
ProfitLoss
-3838000 USD
CY2013Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 USD
CY2014Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 USD
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-2228000 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-3838000 USD
CY2013Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.05
CY2014Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.07
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44601396 shares
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58324260 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
185000 shares
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
117500 USD
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2500000 USD
CY2014Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4000 USD
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
457000 USD
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
362000 USD
CY2013Q1 us-gaap Depreciation
Depreciation
11000 USD
CY2014Q1 us-gaap Depreciation
Depreciation
3000 USD
CY2013Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-275000 USD
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-259000 USD
CY2013Q1 syn Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
-22000 USD
CY2014Q1 syn Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
2000 USD
CY2013Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-199000 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
631000 USD
CY2013Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
0 USD
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-885000 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1662000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3470000 USD
CY2013Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3000 USD
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-3000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-4000 USD
CY2013Q1 syn Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises
ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises
231000 USD
CY2014Q1 syn Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises
ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises
4000 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
231000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4000 USD
CY2013Q1 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-1434000 USD
CY2014Q1 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-3470000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9954000 USD
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8520000 USD
CY2013Q1 us-gaap Interest Paid
InterestPaid
0 USD
CY2014Q1 us-gaap Interest Paid
InterestPaid
0 USD
CY2013Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2014Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2014Q1 dei Document Type
DocumentType
10-Q
CY2014Q1 dei Amendment Flag
AmendmentFlag
false
CY2014Q1 dei Document Period End Date
DocumentPeriodEndDate
2014-03-31
CY2014Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q1 dei Trading Symbol
TradingSymbol
SYN
CY2014Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58453528 shares
CY2014Q1 dei Entity Registrant Name
EntityRegistrantName
Synthetic Biologics, Inc.
CY2014Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000894158
CY2014Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2017Y

Files In Submission

Name View Source Status
0001144204-14-031292-index-headers.html Edgar Link pending
0001144204-14-031292-index.html Edgar Link pending
0001144204-14-031292.txt Edgar Link pending
0001144204-14-031292-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
syn-20140331.xml Edgar Link completed
syn-20140331.xsd Edgar Link pending
syn-20140331_cal.xml Edgar Link unprocessable
syn-20140331_def.xml Edgar Link unprocessable
syn-20140331_lab.xml Edgar Link unprocessable
syn-20140331_pre.xml Edgar Link unprocessable
tpg12.jpg Edgar Link pending
v377580_10q.htm Edgar Link pending
v377580_ex31-1.htm Edgar Link pending
v377580_ex31-2.htm Edgar Link pending
v377580_ex32-1.htm Edgar Link pending
v377580_ex32-2.htm Edgar Link pending